Applied UV Installs Patented LumiCide Surface Disinfection Solution into NYC’s Mt. Sinai Medical Center Morningside
14 June 2022 - 10:00PM
Business Wire
One of The World’s Prestigious
Hospitals
Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the
“Company”), a pathogen elimination technology company that applies
the power of narrow-range ultraviolet light (“UVC”) for surface
areas and catalytic bioconversion technology for air purification
to destroy pathogens safely, thoroughly, and automatically,
announces that its wholly owned subsidiary SteriLumen has just
installed its patented LumiCide Surface and Drain UVC Disinfecting
Systems initially, in 17 patient rooms within the world renowned
Mt. Sinai Medical Center Morningside. Mount Sinai Morningside,
formerly known as Mount Sinai St. Luke's, is a teaching hospital
located in the Morningside Heights neighborhood of Manhattan in New
York City.
Mt. Sinai plans to publish the results in an Academic Paper
later this summer which would further validate the previously
obtained independent results conducted by ResInnova Laboratories.
This validation could facilitate the adoption of our LumiCide
Surface and Drain disinfection solutions throughout healthcare
facilities globally.
Mount Sinai Morningside is affiliated with the Icahn School of
Medicine at Mount Sinai and the Mount Sinai Health System, a
nonprofit hospital system formed by the merger of Continuum Health
Partners and the Mount Sinai Medical Center in September 2013. It
provides general medical and surgical facilities, ambulatory care,
and a Level 2 Trauma Center, verified by the American College of
Surgeons. It operates 21 clinics and as of 2020, is nationally
ranked by U.S. News & World Report.
John F. Andrews Applied UV’s CEO and Director stated, “We
welcome Mt. Sinai Medical Center to the Applied UV Family. The
addition of this premier, globally recognized, and respected
teaching institution to our growing list of leading hospitals who
place their trust in our patented disinfection products (both air
and surface) is further testament to the proven effectiveness but
also, too the growing interest of globally recognized brands and
companies who use our family of solutions to protect their
facilities, employees, and products from harmful airborne and
surface related pathogens. We look forward to a long and successful
relationship with the Mt. Sinai team.”
The LumiCide Disinfection System product line has the following
attributes:
- Focus on the sink area and
drain. Focuses on pathogens
that accumulate on the sink area, including handles, faucets and
backsplash and in the drain.
- UVC LED Pathogen
Destruction. Destroys 4 logs (99.99%) some of the most
dangerous pathogens like COVID 19, MERSA C’diff, in the bathroom
vanity/sink area with at least two hours of continuous use.
- Automatic operation.
Built-in programmable controller that ensures operation for the
full required daily time and is not dependent on manual
operation.
- Continuous operation. Works
in cycles of two hour on and four hours off, except for the
disinfecting drain which is on 15 minutes every hour. The timing
protocol is managed by a programmable controller and a motion
detector enclosed within each device and works while the room is
still occupied and while the bathroom is not in use, therefore,
continuously disinfecting an area of ongoing high
contamination.
- Safety. Built-in motion
detector and sensor automatically shuts off the UVC light when
anyone enters the room eliminating any concern over UV safety. Once
there is no movement in the room for 10 minutes the UVC light comes
back on to restart and continue its cycle.
- Removable UVC LED panel.
The UVC LEDs are installed via a removable panel, leading to ease
of replacement or upgrade.
- Ease of Installation. The
unit is easy to install and uses standard electrical wiring.
- IOT connectivity. IOT
connectivity uses Wi-Fi and RF technology that will enable
continuous transmission of use and functionality data over the
Internet for collection and analysis.
Applied UV’s internal research and research provided by the CDC
estimates that each year about 1 in 25 U.S. hospital patients
(approximately 1.4M Americans) are diagnosed with at least one
infection related to hospital care alone and additional infections
occur in other healthcare settings. Approximately 900,000 Americans
die each year due to complications associated with Hospital
Acquired Infections. Many HAI’s are caused by the most urgent and
serious antibiotic -resistant (AR) bacteria and my lead to sepsis
of death. According to NIH, Healthcare-associated infections are
known to increase the length of stay, health care costs, and
mortality. Each year the top 5 healthcare-associated infections
result in about $9.8 billion costs.
About Applied UV
Applied UV is focused on the development and acquisition of
technology that address infection control in the healthcare,
hospitality, commercial and municipal markets. The Company has two
wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and
Munn Works, LLC (“Munn Works”). SteriLumen’s connected platform for
Data Driven Disinfection™ applies the power of ultraviolet light
(UVC) to destroy pathogens safely, thoroughly, and automatically,
addressing the challenge of healthcare-acquired infections
("HAIs"). Targeted for use in facilities that have high customer
turnover such as hospitals, hotels, commercial facilities, and
other public spaces, the Company’s Lumicide™ platform uses UVC LEDs
in several patented designs for infection control in and around
high-traffic areas, including sinks and restrooms, killing
bacteria, viruses, and other pathogens residing on hard surfaces
within devices’ proximity. The Company’s patented in-drain
disinfection device, Lumicide Drain, is the only product on the
market that addresses this critical pathogen intensive location.
SteriLumen’s Airocide® air purification devices are research
backed, clinically proven, and developed for NASA with assistance
from the University of Wisconsin. Airocide® is listed as an FDA
Class II Medical device, utilizes a proprietary photocatalytic
(PCO) bioconversion technology that draws air into a reaction
chamber that converts damaging molds, microorganisms, dangerous
airborne pathogens, destructive VOCs, allergens, odors and
biological gasses into harmless water vapor and green carbon
dioxide without producing ozone or other harmful byproducts.
Airocide® applications include healthcare, hospitality, grocery
chains, wine making facilities, commercial real estate, schools,
dental offices, post-harvest, grocery, cannabis facilities and
homes. For more information about Applied UV, Inc., and its
subsidiaries, please visit the following websites:
https://www.applieduvinc.com
Forward-Looking Statements
The information contained herein may contain “forward‐looking
statements.” Forward‐looking statements reflect the current view
about future events. When used in this press release, the words
“anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,”
“plan,” or the negative of these terms and similar expressions, as
they relate to us or our management, identify forward‐looking
statements. Such statements include, but are not limited to,
statements contained in this press release relating to the view of
management of Applied UV concerning its business strategy, future
operating results and liquidity and capital resources outlook.
Forward‐looking statements are based on the Company’s current
expectations and assumptions regarding its business, the economy
and other future conditions. Because forward–looking statements
relate to the future, they are subject to inherent uncertainties,
risks and changes in circumstances that are difficult to predict.
The Company’s actual results may differ materially from those
contemplated by the forward‐looking statements. They are neither
statements of historical fact nor guarantees of assurance of future
performance. We caution you therefore against relying on any of
these forward‐looking statements. Factors or events that could
cause the Company’s actual results to differ may emerge from time
to time, and it is not possible for the Company to predict all of
them. The Company cannot guarantee future results, levels of
activity, performance, or achievements. Except as required by
applicable law, including the securities laws of the United States,
the Company does not intend to update any of the forward‐looking
statements to conform these statements to actual results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220614005359/en/
Applied UV Inc. John F. Andrews Applied UV CEO & Director
john.andrews@applieduvinc.com
Brett Maas, Managing Principal Hayden IR brett@haydenir.com
(646) 536-7331
Applied UV (NASDAQ:AUVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied UV (NASDAQ:AUVI)
Historical Stock Chart
From Apr 2023 to Apr 2024